McDonald's Corp vs Sana Biotechnology Inc — how do they compare? McDonald's Corp trades at $273.1 (market cap $194.00B), while Sana Biotechnology Inc trades at $3.78 (market cap $1.13B). The key difference: McDonald's Corp is far larger — about 171.7× Sana Biotechnology Inc's market cap, and McDonald's Corp pays a 2.71% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| MCD | SANA | |
|---|---|---|
Market Cap | $194.00B | $1.13B |
Volume | 2,230,036 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $5.92 |
52-Week Low | $262.80 | $2.68 |
Enterprise Value | $247.77B | $1.05B |
Dividend Yield | 2.71% | — |
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $273.72, down 0.28% on the day, with a neutral technical signal and strong fundamentals including a 31.72% net margin and consistent earnings beats. The company recently unveiled its 'McDonald's NEXT' growth strategy focusing on automation and menu innovation to drive future performance. Revenue growth remains steady, with 2025 revenue at $26.89 billion.
Outlook is positive with a consensus price target of $322.45 offering 17.8% upside, supported by 60% analyst buy ratings. Risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. The stock presents a value opportunity with stable dividends and strategic initiatives aimed at enhancing competitiveness.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →